NOVEL PYRIMIDINIMIDAZOLAMINES AS MODULATORS OF KINASE ACTIVITY Russian patent published in 2019 - IPC C07D401/14 A61K31/506 A61P35/00 

FIELD: chemistry.

SUBSTANCE: invention relates to a novel imidazolamine compound selected from the group given below. Compounds possess inhibitory action on activity of serine-protein kinase p70S6K and Akt and can be used for treating cancer, particularly bladder cancer and pancreatic cancer. Novel compound is selected from 6-{4-[1-(2-azetidin-1-yl-ethyl)-4-(4-fluoro-3-methyl-phenyl)-1H-imidazol-2-yl]-piperidin-1-yl}-5-ethyl-pyrimidin-4-ylamine; 6-{4-[1-(2-azetidin-1-yl-ethyl)-4-(2-isopropyl-pyridin-4-yl)-1H-imidazol-2-yl]-piperidin-1-yl}-5-isopropyl-pyrimidin-4-ylamine; 6-{4-[1-(2-azetidin-1-yl-ethyl)-4-(4-fluoro-3-methyl-phenyl)-1H-imidazol-2-yl]-piperidin-1-yl}-5-isopropyl-pyrimidin-4-ylamine; 5-chloro-6-{4-[4-(4-fluoro-3-methyl-phenyl)-1-(1-methyl-azetidin-3-ylmethyl)-1H-imidazol-2-yl]-piperidin-1-yl}-pyrimidin-4-ylamine; 6-{4-[1-(2-azetidin-1-yl-ethyl)-4-(4-fluoro-3-methyl-phenyl)-1H-imidazol-2-yl]-piperidin-1-yl}-5-pyridin-4-yl-pyrimidin-4-ylamine; 6-{4-[1-(2-azetidin-1-yl-ethyl)-4-(4-fluoro-3-methyl-phenyl)-1H-imidazol-2-yl]-piperidin-1-yl}-5-pyridin-3-yl-pyrimidin-4-ylamine; 6-{4-[1-(2-azetidin-1-yl-ethyl)-4-(2-isopropyl-pyridin-4-yl)-1H-imidazol-2-yl]-piperidin-1-yl}-5-ethoxy-pyrimidin-4-ylamine; 6-{4-[1-(2-azetidin-1-yl-ethyl)-4-(2-isopropyl-pyridin-4-yl)-1H-imidazol-2-yl]-piperidin-1-yl}-5-cyclobutyl-pyrimidin-4-ylamine; 6-{4-[1-(2-azetidin-1-yl-ethyl)-4-(4-fluoro-3-methyl-phenyl)-1H-imidazol-2-yl]-piperidin-1-yl}-5-cyclopropyl-pyrimidin-4-ylamine; 5-bromo-6-{4-(3-methyl-4-fluorophenyl)-1-[2-(dimethylamino-1-yl-ethyl)-1H-imidazol-2-yl]-piperidin-1-yl}-pyrimidin-4-ylamine; 5-chloro-6-{4-(3-methyl-4-fluorophenyl)-1-[2-(dimethylamino-1-yl-ethyl)-1H-imidazol-2-yl]-piperidin-1-yl}-pyrimidin-4-ylamine; and 6-{4-[1-(2-ethylamino-ethyl)-4-(4-fluoro-3-trifluoromethyl-phenyl)-1H-imidazol-2-yl]-piperidin-1-yl}-5-isopropyl-pyrimidin-4-ylamine.

EFFECT: each of said compounds has inhibitory effect 2 times or more greater than activity (IC50) of the closest-known compound with respect to Akt.

4 cl, 4 tbl, 1 ex